767 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Purchased by Occudo Quantitative Strategies LP

Occudo Quantitative Strategies LP purchased a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 767 shares of the company's stock, valued at approximately $317,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. United Capital Financial Advisors LLC increased its stake in shares of IDEXX Laboratories by 0.9% in the fourth quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock worth $1,011,000 after acquiring an additional 22 shares during the period. Cranbrook Wealth Management LLC increased its stake in shares of IDEXX Laboratories by 7.0% in the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock worth $158,000 after acquiring an additional 25 shares during the period. Gabelli Funds LLC increased its stake in shares of IDEXX Laboratories by 5.3% in the fourth quarter. Gabelli Funds LLC now owns 500 shares of the company's stock worth $207,000 after acquiring an additional 25 shares during the period. Perigon Wealth Management LLC increased its stake in shares of IDEXX Laboratories by 1.8% in the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock worth $632,000 after acquiring an additional 26 shares during the period. Finally, Summit Trail Advisors LLC increased its stake in shares of IDEXX Laboratories by 3.3% in the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock worth $335,000 after acquiring an additional 26 shares during the period. Hedge funds and other institutional investors own 87.84% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Stifel Nicolaus increased their price objective on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research note on Monday. Morgan Stanley raised their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research report on Monday, May 5th. Barclays upped their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Finally, Bank of America lifted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and a consensus price target of $536.00.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX traded down $4.52 during trading on Tuesday, hitting $517.16. The company had a trading volume of 606,894 shares, compared to its average volume of 648,678. The stock has a fifty day simple moving average of $433.47 and a two-hundred day simple moving average of $432.18. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $545.43. The firm has a market capitalization of $41.59 billion, a price-to-earnings ratio of 48.47, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The business had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. During the same quarter last year, the business earned $2.71 earnings per share. The company's revenue for the quarter was up 3.6% compared to the same quarter last year. On average, research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.